ReviewJournal of controlled release : official journal of the Controlled Release Society2021
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 55 citations in OpenAlex.
- Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.Discover nano · 2025Review
- Hematological, inflammatory, and novel biomarkers assessment as an eminent strategy for clinical management of COVID-19.Heliyon · 2023Article
- Bioenergy-Based Closed-Loop Medical Systems for the Integration of Treatment, Monitoring, and Feedback.Small science · 2023Article
- The Role of Pro-Inflammatory Mediator Interleukin-32 in Osteoclast Differentiation.Turkish journal of pharmaceutical sciences · 2023Article
- Graphene oxide and flavonoids as potential inhibitors of the spike protein of SARS-CoV-2 variants and interaction between ligands: a parallel study of molecular docking and DFT.Structural chemistry · 2023Article
- Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design.Scientific reports · 2022Article
- Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022?Journal of global health · 2022Article
- Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.Nanomaterials (Basel, Switzerland) · 2022Review
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
- Advances in the use of nanomaterials for nucleic acid detection in point-of-care testing devices: A review.Frontiers in bioengineering and biotechnology · 2022Review
- A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in early 2020 soon led to the global pandemic of Coronavirus Disease 2019 (COVID-19). Since then, the clinical and scientific communities have been closely collaborating to develop effective strategies for controlling the ongoing pandemic. The game-changing fields of recent years, nanotechnology and nanomedicine have the potential to not only design new approaches, but also to improve existing methods for the fight against COVID-19. Nanomaterials can be used in the development of highly efficient, reusable personal protective equipment, and antiviral nano-coatings in public settings could prevent the spread of SARS-CoV-2. Smart nanocarriers have accelerated the design of several therapeutic, prophylactic, or immune-mediated approaches against COVID-19. Some nanovaccines have even entered Phase IΙ/IIΙ clinical trials. Several rapid and cost-effective COVID-19 diagnostic techniques have also been devised based on nanobiosensors, lab-on-a-chip systems, or nanopore technology. Here, we provide an overview of the emerging role of nanotechnology in the prevention, diagnosis, and treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.